Opportunities and Challenges
Immunotherapy has revolutionized cancer therapy leading to dramatically improved outcomes, successes that can inspire precision medicines to enhance antimicrobial function of innate immune cells for infectious disease indications. Host direct therapies can help cure or prevent deep tissue foci of antibiotic-resistant pathogens with minimal collateral damage on our microbiota. Theoretical concerns exist regarding the pro-inflammatory consequences of immune activating therapy, however uncontrolled antibiotic-resistant infections themselves cause severe deleterious inflammatory effects on the host until effective medical cure is achieved, and that wise host immune pathway targeting can overcome such hurdles.